CR7444A - Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos - Google Patents
Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativosInfo
- Publication number
- CR7444A CR7444A CR7444A CR7444A CR7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A CR 7444 A CR7444 A CR 7444A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- epotilones
- diseases associated
- proliferative processes
- cerebral diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Uso de una epotilona que presenta un coeficiente de distribucion promedio entre plasma y cerebro que comprende entre 0,3 y 1,5 en el ensayo de inyeccion de bolo intravenoso en raton, en la preparacion de un medicameto para el tratamiento de una enfermedad cerebral asociada con proesosos proliferativos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02004745A EP1340498A1 (en) | 2002-03-01 | 2002-03-01 | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7444A true CR7444A (es) | 2005-10-05 |
Family
ID=27675676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7444A CR7444A (es) | 2002-03-01 | 2004-09-01 | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos |
Country Status (23)
Country | Link |
---|---|
US (1) | US20040019088A1 (es) |
EP (2) | EP1340498A1 (es) |
JP (1) | JP2005525360A (es) |
KR (1) | KR20040095244A (es) |
CN (1) | CN100473381C (es) |
AR (1) | AR038712A1 (es) |
AU (1) | AU2003215618B2 (es) |
BR (1) | BR0308154A (es) |
CA (1) | CA2477403A1 (es) |
CR (1) | CR7444A (es) |
EC (1) | ECSP045340A (es) |
HK (1) | HK1079998A1 (es) |
HR (1) | HRP20040892A2 (es) |
IL (1) | IL163752A0 (es) |
MX (1) | MXPA04008450A (es) |
NO (1) | NO20044175L (es) |
NZ (1) | NZ546617A (es) |
PL (1) | PL370768A1 (es) |
RU (1) | RU2351330C2 (es) |
UA (1) | UA83798C2 (es) |
WO (1) | WO2003074053A1 (es) |
YU (1) | YU76404A (es) |
ZA (1) | ZA200407905B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
AU9340998A (en) * | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
SK11452001A3 (sk) * | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Deriváty epotilónu, farmaceutický prípravok s ich obsahom a ich použitie |
AU772750C (en) * | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
JP4791183B2 (ja) | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体、類似体の合成およびその使用 |
DE10331004A1 (de) * | 2003-07-03 | 2005-02-24 | Schering Ag | Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP1700596A1 (en) * | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
ES2501565T3 (es) * | 2008-04-24 | 2014-10-02 | Bristol-Myers Squibb Company | Uso de epotilona D en el tratamiento de enfermedades asociadas a Tau incluyendo enfermedad de Alzheimer |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
AU2014283185B2 (en) | 2013-06-21 | 2019-05-02 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT833828E (pt) * | 1995-06-09 | 2003-02-28 | Novartis Ag | Derivados de rapamicina |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
IL131447A0 (en) * | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
AU9340998A (en) * | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
DE69818304T2 (de) * | 1997-12-04 | 2004-07-01 | Bristol-Myers Squibb Co. | Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
WO1999067253A2 (en) * | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
IL144519A0 (en) * | 1999-02-18 | 2002-05-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
EP2266607A3 (en) * | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
GB0013643D0 (en) * | 2000-05-31 | 2000-07-26 | Unilever Plc | Targeted moieties for use in bleach catalysts |
JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
-
2002
- 2002-03-01 EP EP02004745A patent/EP1340498A1/en not_active Withdrawn
-
2003
- 2003-02-28 YU YU76404A patent/YU76404A/sh unknown
- 2003-02-28 IL IL16375203A patent/IL163752A0/xx unknown
- 2003-02-28 CN CNB038097613A patent/CN100473381C/zh not_active Expired - Fee Related
- 2003-02-28 CA CA002477403A patent/CA2477403A1/en not_active Abandoned
- 2003-02-28 KR KR10-2004-7013549A patent/KR20040095244A/ko not_active Application Discontinuation
- 2003-02-28 WO PCT/EP2003/002085 patent/WO2003074053A1/en active Application Filing
- 2003-02-28 JP JP2003572570A patent/JP2005525360A/ja active Pending
- 2003-02-28 BR BR0308154-0A patent/BR0308154A/pt not_active Withdrawn
- 2003-02-28 NZ NZ546617A patent/NZ546617A/en unknown
- 2003-02-28 EP EP03743360A patent/EP1480643A1/en not_active Withdrawn
- 2003-02-28 RU RU2004129325/15A patent/RU2351330C2/ru active
- 2003-02-28 AU AU2003215618A patent/AU2003215618B2/en not_active Expired - Fee Related
- 2003-02-28 UA UA20040907817A patent/UA83798C2/ru unknown
- 2003-02-28 US US10/375,043 patent/US20040019088A1/en not_active Abandoned
- 2003-02-28 MX MXPA04008450A patent/MXPA04008450A/es not_active Application Discontinuation
- 2003-02-28 PL PL03370768A patent/PL370768A1/xx not_active Application Discontinuation
- 2003-03-03 AR ARP030100696A patent/AR038712A1/es unknown
-
2004
- 2004-09-01 CR CR7444A patent/CR7444A/es not_active Application Discontinuation
- 2004-09-28 HR HRP20040892 patent/HRP20040892A2/hr not_active Application Discontinuation
- 2004-09-30 NO NO20044175A patent/NO20044175L/no not_active Application Discontinuation
- 2004-09-30 ZA ZA200407905A patent/ZA200407905B/en unknown
- 2004-09-30 EC EC2004005340A patent/ECSP045340A/es unknown
-
2006
- 2006-01-04 HK HK06100157.3A patent/HK1079998A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1649587A (zh) | 2005-08-03 |
AU2003215618B2 (en) | 2009-06-04 |
EP1340498A1 (en) | 2003-09-03 |
RU2004129325A (ru) | 2005-07-10 |
IL163752A0 (en) | 2005-12-18 |
EP1480643A1 (en) | 2004-12-01 |
CN100473381C (zh) | 2009-04-01 |
ZA200407905B (en) | 2006-04-26 |
ECSP045340A (es) | 2004-11-26 |
AR038712A1 (es) | 2005-01-26 |
HK1079998A1 (zh) | 2006-04-21 |
KR20040095244A (ko) | 2004-11-12 |
YU76404A (sh) | 2006-08-17 |
BR0308154A (pt) | 2005-01-04 |
NO20044175L (no) | 2004-12-01 |
PL370768A1 (en) | 2005-05-30 |
RU2351330C2 (ru) | 2009-04-10 |
WO2003074053A1 (en) | 2003-09-12 |
UA83798C2 (ru) | 2008-08-26 |
CA2477403A1 (en) | 2003-09-12 |
HRP20040892A2 (en) | 2004-12-31 |
AU2003215618A1 (en) | 2003-09-16 |
JP2005525360A (ja) | 2005-08-25 |
US20040019088A1 (en) | 2004-01-29 |
NZ546617A (en) | 2007-12-21 |
MXPA04008450A (es) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7444A (es) | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
BG105575A (en) | Method and agent for the treatment of cerebral ischaemia | |
TW200642704A (en) | Oral drug delivery system and methods of use thereof | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
ES2422286T3 (es) | Uso de apamina para tratar la enfermedad de Parkinson | |
WO2006012521A3 (en) | Treatment for ocular disease | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
D'Orazio et al. | 44th annual meeting of the American Society of Hematology. December 7-10, 2002: Philadelphia, Pennsylvania. Short-course chemotherapy without radiation therapy could be sufficient for elderly patients with localized aggressive non-Hodgkin's lymphoma | |
AR027152A1 (es) | Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva. | |
ECSP993003A (es) | Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC90 | Application suspended |